HYPERRAB

This brand name is authorized in Canada, Hong Kong, Singapore, United States

Active ingredients

The drug HYPERRAB contains one active pharmaceutical ingredient (API):

1 Human rabies immunoglobulin UNII 95F619ATQ2 - HUMAN RABIES VIRUS IMMUNE GLOBULIN

Human rabies immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against rabies virus. Human Rabies Immunoglobulin must always be used in combination with a rabies vaccine. Read about Human rabies immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HYPERRAB Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BB05	Rabies immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02486571
Country: HK	Department of Health Drug Office	Identifier(s): 54931
Country: SG	Health Sciences Authority	Identifier(s): 09657P
Country: US	FDA, National Drug Code	Identifier(s): 13533-318, 13533-618